TickerTalks
Browse all tickers →
TickerTalks›$IONS
IOIONS

Ionis Pharmaceuticals, Inc.

$IONS·$9.4B·Biotechnology·Healthcare
$57.24+2.5%YTD-31.1%1Y+33.6%
Mentions · last 7 days
2026-08-07: 4 posts2026-08-08: 1 posts2026-08-09: 4 posts2026-08-10: 9 posts2026-08-11: 7 posts2026-08-12: 3 posts2026-08-13: 5 posts330%
Price updated 2d ago·X counts updated 3d ago
IOIONS
$IONSIonis Pharmaceuticals, Inc.
$57.24+2.45%33 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $IONS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptWinding up for a moveAI verdict · as of 2026-08-14

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Ionis Pharmaceuticals down 31% YTD after CARDIO-TTRansform Phase 3 failure — Director Hayden bought $1.1M in July, and JPM raised PT to $76.

Ionis Pharmaceuticals is an antisense-oligonucleotide biotech — the specific RNA-drug-development franchise where CARDIO-TTRansform failure is the specific structural setback, and the current setup is whether the pipeline-plus-insider signal supports a coiled-with-upward-bias positioning.

  • The Q1 mechanics were mechanically strong: revenue of $246M grew 87% YoY at a 98% gross margin, EPS of -$0.56 beat consensus of -$0.85 by 34% — for a business at 12x TTM sales with -11% ROIC and consensus FY26 EPS of -$3.55, the specific mechanical improvement is real, though the CARDIO-TTRansform failure is a specific setback that removed a key catalyst.
  • The insider signal is unusually strong: Director Michael Hayden made P-Purchases of 15,000 + 5,000 shares (~$1M+ total on Jul 30-31) — that's the specific fresh-conviction signal from a director after the CARDIO-TTRansform failure, and JPMorgan raising the PT from $72 to $76 (Overweight) plus all major 13F holders reported so far buying the dip supports the specific institutional-conviction framing.
  • The sHTG market thesis is the specific structural anchor: users frame IONS as capturing at least 40% of the sHTG (severe hypertriglyceridemia) market versus ARWR's cash burn — that's the specific commercial-opportunity where the underlying pipeline economics support the current $9.4B market cap, and the securities-investigation drag (Pomerantz, SBS Law) is the specific structural counter-signal.

What resolves the coil upward is the Nov 4 print confirming Q2's revenue trajectory continues plus specific commentary on any pipeline advancement replacing CARDIO-TTRansform; what breaks it down is another Phase 3 clinical failure or a specific investigation-to-complaint escalation.

Agrees with X sentimentThe bullish X read has the specific facts right — JPMorgan raising the PT from $72 to $76 (Overweight), director Michael Hayden's July insider purchases of 15,000 + 5,000 shares (~$1M total), all major 13F holders reported so far buying the dip, and IONS capturing at least 40% of the sHTG market versus ARWR's cash burn are all real and support the coiled-with-upward-bias positioning.

What to watch: Nov 4 Q3 earnings — revenue trajectory, pipeline advancement replacing CARDIO-TTRansform, and any securities-investigation status. Another Phase 3 failure or investigation-to-complaint escalation is what breaks the coil down.

On the calendar: 2026-11-04 — Q3 earnings

securities investigation

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment40 posts analyzed · as of 2026-08-11

Ionis Pharmaceuticals posters cheer JPMorgan raising the PT from $72 to $76 (Overweight), director Michael Hayden's July insider purchases of 15,000 + 5,000 shares (~$1M total), and all major 13F holders reported so far buying the dip. Users frame IONS as capturing at least 40% of the sHTG market versus ARWR's cash burn. Sentiment is decisively bullish on insider-signal.

Read the AI verdict + X sentiment for $IONS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Pioneer in RNA-targeted antisense therapies with approved drugs for spinal muscular atrophy and hereditary transthyretin amyloidosis, and a broad Phase 3 pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $IONS.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $IONS

Neutral — Pioneer in RNA-targeted antisense therapies with approved drugs for spinal muscular atrophy and hereditary transthyretin amyloidosis, and a broad Phase 3 pipeline; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+44.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-39.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-11.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-33.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-7.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
12.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-58.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
98.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
4.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 29, 2026$-0.69$-1.08+36.1%
Q1 2026Apr 29, 2026$-0.56$-0.85+34.1%
Q4 2025Feb 25, 2026$-1.41$-1.24-14.0%
Q3 2025Oct 29, 2025$-0.61$-1.15+47.0%
Next earningsWed, Nov 4·consensus EPS $-1.21

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$246.1M+87.0%98.8%-47.7%$-0.56$-814.6M
Q4 FY25$203.0M-10.4%96.1%-106%$-1.41$-159.0M
Q3 FY25$156.7M+17.1%98.5%-102%$-0.80$-134.7M
Q2 FY25$452.0M+100.7%99.1%30.9%$0.78$137.1M

Forward consensus

5-year forecast · up to 17 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$920.1M$914.5M – $925.8M-$3.55-$3.65 – -$3.4212
FY27$1.4B$1.2B – $1.7B-$1.79-$2.78 – $0.0717
FY28$2.0B$1.7B – $2.6B$0.54-$12.21 – $13.8316
FY29$2.6B$2.3B – $3.3B$3.13$2.66 – $4.1715
FY30$3.3B$2.9B – $4.1B$5.77$4.91 – $7.6915

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.34%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-12.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-23.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 162.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.405-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyJul 31Michael R HaydenDirector5.0K sh$258KBuyJul 30Michael R HaydenDirector15.0K sh$801KSellJul 7Allene M. DiazDirector10.1K sh$864KSellJul 7Holly B. KordasiewiczEVP, Chief Development Officer362 sh$31KSellJul 7Bennett C FrankEVP, Chief Scientific Officer20.5K sh$1.7MSellJul 1Klein Joseph IiiDirector11.5K sh$910KSellJun 26Joseph BaroldiEVP, Chief Business Officer5.6K sh$452KSellJun 26Patrick R. O'neilEVP CLO & General Counsel3.1K sh$246KSellJun 26Eugene SchneiderEVP, Chf Clinical Develop Ofcr26.0K sh$2.1MSellJun 26Brett P MoniaCEO50.0K sh$4.0M
1–10 of 18
+ 27 other (15 exempts · 11 awards · 1 other) in window

See when $IONS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJul 108-K — Item 7.01: Press release / Reg FD
AI summary

Ionis Pharmaceuticals, Inc. reaffirmed its previously announced full-year 2026 financial guidance, unchanged from the guidance provided on April 29, 2026 in the Q1 2026 earnings release. The disclosure was filed under Regulation FD as a non-filed informational update. This is a routine guidance reaffirmation — no change in business outlook, signaling steady operational performance from Ionis heading into Q2.

8-KPress release / Reg FDJul 98-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Ionis Pharmaceuticals disclosed that its CARDIO-TTRansform Phase 3 clinical trial evaluating eplontersen for ATTR cardiomyopathy (ATTR-CM) failed to meet its primary endpoint. This is a significant negative clinical outcome as ATTR-CM represents a large potential market, and eplontersen was seen as a key pipeline asset for Ionis and its partner AstraZeneca. The failure eliminates a major revenue opportunity for the partnership, though eplontersen remains approved in the polyneuropathy indication under the brand name Wainua. Shares would be expected to react sharply negative on this news.

8-KPress release / Reg FDJun 248-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

The FDA approved Ionis's TRYNGOLZA (olezarsen) as an adjunct to diet to reduce triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia (triglycerides 500 mg/dL or higher) on June 24, 2026. Major FDA approval for olezarsen in a rare lipid disorder; adds a commercial product to Ionis's portfolio.

3New insider — initial holdingsJun 83
AI summary

Peter N. Reikes (director, Carlsbad CA) filed a Form 3 initial beneficial ownership statement for Ionis Pharmaceuticals as of June 4, 2026. Administrative disclosure for a newly appointed Ionis director.

3New insider — initial holdingsJun 83
AI summary

Ludwig Hantson (director, Carlsbad CA) filed a Form 3 initial beneficial ownership statement for Ionis Pharmaceuticals as of June 4, 2026. Administrative disclosure for a newly appointed Ionis director.

8-KOfficer or director changeJun 88-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote · Item 7.01: Press release / Reg FD
AI summary

Ionis appointed Ludwig Hantson (former Alexion CEO 2017-2021; prior Baxter Bioscience president who led the Baxalta spin-off) as independent director effective June 4, 2026, immediately following the 2026 Annual Meeting. Strong board addition with rare disease and large-cap biopharma leadership experience directly relevant to Ionis's pipeline.

8-KPress release / Reg FDMay 288-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Ionis issued a Reg FD disclosure announcing that its partner GSK reported positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB), on May 28, 2026 (press release in Exhibit 99.1). Positive partner clinical trial data for a key Ionis-partnered ASO in hepatitis B; potential commercial milestone.

8-KPress release / Reg FDApr 218-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
+ 17 other (5 13Gs · 3 earnings 8-Ks · 2 10-Qs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?fool.com·2d agoIONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Lawgurufocus.com·8d agoIONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Lawbusinesswire.com·8d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONSprnewswire.com·10d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONSglobenewswire.com·12d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ABCL$CAPR$ALLO$NWBO$TENX$AURA$SION$IBRX
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport